CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced online publication of a study in the The paper, titled “A Gender Specific Blood-Based Gene Expression ...
CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for ...
Coronary artery disease kills more women than all cancers combined, yet the clinical picture in women is different enough from men that the diagnosis can be missed or delayed. A cardiologist ...
CLEVELAND, OH — The age/sex/gene-expression score (ASGES) test known as Corus CAD (CardioDx) appears easy to incorporate and effective in excluding obstructive coronary artery disease (CAD) in ...
Blood-Based Test Has Potential to Improve Quality of Care and Lower Costs of Evaluation of Obstructive Coronary Artery Disease REDWOOD CITY, Calif. – CardioDx, Inc., a molecular diagnostics company ...
Coverage of Blood-Based Test Has Potential to Improve Quality of Care and Lower Costs of Diagnosis of Obstructive Coronary Artery Disease Beyond Traditional Methods PALO ALTO, Calif. – CardioDx, Inc., ...
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback